12.08
3.65%
-0.5228
전일 마감가:
$12.60
열려 있는:
$12.7
하루 거래량:
80,023
Relative Volume:
0.49
시가총액:
$627.09M
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-8.5624
EPS:
-1.4105
순현금흐름:
$-97.30M
1주 성능:
-0.25%
1개월 성능:
-12.22%
6개월 성능:
-5.96%
1년 성능:
+101.66%
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
MLYS | 12.13 | 627.09M | 0 | -119.67M | -97.30M | -1.4105 |
VRTX | 447.03 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 741.05 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 587.61 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.22 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.84 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-03-07 | 개시 | BofA Securities | Buy |
2023-03-07 | 개시 | Credit Suisse | Outperform |
2023-03-07 | 개시 | Evercore ISI | Outperform |
2023-03-07 | 개시 | Guggenheim | Buy |
2023-03-07 | 개시 | Stifel | Buy |
2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN
Mineralys Therapeutics to Participate in Goldman Sachs Healthcare Conference - MSN
Mineralys Therapeutics Set to Engage with Investors at Key Conferences - MSN
Mineralys Therapeutics Inc (MLYS) Quarterly 10-Q Report - Quartzy
What is Lifesci Capital's Forecast for MLYS FY2024 Earnings? - MarketBeat
HC Wainwright Analysts Decrease Earnings Estimates for MLYS - MarketBeat
(MLYS) Trading Signals - Stock Traders Daily
Mineralys therapeutics CMO sells shares worth $75,398 By Investing.com - Investing.com Australia
MineralysTargeting Aldosterone To Combat Obesity-Driven Hypertension And Kidney Disease - RTTNews
Mineralys Therapeutics Announces Q3 2024 Results and Updates - Yahoo Finance
Mineralys Therapeutics' (MLYS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q3 2024 Earnings Call Transcript - MSN
Mineralys Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Mineralys Therapeutics reports Q3 EPS ($1.13), consensus (83c) - TipRanks
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
David Malcom Rodman Sells 25,482 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics' chief medical officer sells $383,065 in stock - Investing.com
Mineralys Therapeutics to Announce Third-Quarter 2024 Financial Results - MyChesCo
Mineralys Therapeutics (MLYS) to Release Quarterly Earnings on Monday - MarketBeat
Mineralys Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Mineralys Therapeutics (MLYS) to Present at Three Major Healthcare Conferences | MLYS Stock News - StockTitan
Mineralys Therapeutics to Announce Third Quarter 2024 - GlobeNewswire
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024 - Marketscreener.com
Mineralys Therapeutics’ (MLYS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Objective long/short (MLYS) Report - Stock Traders Daily
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial - MSN
Mineralys Therapeutics (NASDAQ:MLYS) Receives "Buy" Rating from HC Wainwright - MarketBeat
Mineralys Therapeutics : Corporate Overview October 2024 - Marketscreener.com
Mineralys Therapeutics Advances Lorundrostat Trial Progress - TipRanks
Mineralys Therapeutics Completes Enrollment Ahead of - GlobeNewswire
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension - The Manila Times
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock - MSN
Context Therapeutics to Engage Investors at November Conferences - MyChesCo
Mineralys Therapeutics to Host Virtual Event on Hypertension Treatment Advances - MyChesCo
When the Price of (MLYS) Talks, People Listen - Stock Traders Daily
Mineralys to Host Virtual KOL Event on the Unmet Medical Need in Uncontrolled and Resistant Hypertension, and Lorundrostat as a Potential Treatment on October 30, 2024 - The Manila Times
Mineralys to Host Virtual KOL Event on the Unmet Medical - GlobeNewswire
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate - Yahoo Finance
Hypertension Clinical Trials 2024: FDA Approvals, Medication, - openPR
Hypertension Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, Companies by DelveInsight | Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Novartis - The Globe and Mail
Mineralys Therapeutics CEO sells $206,433 in stock - Investing.com
Mineralys Therapeutics CEO sells $206,433 in stock By Investing.com - Investing.com Canada
Mineralys therapeutics CFO Adam Levy sells $146,003 in stock By Investing.com - Investing.com South Africa
Mineralys therapeutics CFO Adam Levy sells $146,003 in stock - Investing.com
Mineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 15,271 Shares - GuruFocus.com
Insider Sale: CFO Adam Levy Sells Shares of Mineralys Therapeuti - GuruFocus.com
Adam Scott Levy Sells 10,757 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock - MarketBeat
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):